Patents by Inventor Michael John Scott Saunders

Michael John Scott Saunders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amino acid sequences that modulate the interaction between cells of the immune system
    Patent number: 11858997
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: January 2, 2024
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 11773159
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • ANTIBODIES TO CD70
    Publication number: 20230265201
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: July 11, 2022
    Publication date: August 24, 2023
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Antibodies to CD70
    Patent number: 11434298
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: September 6, 2022
    Assignee: ARGENX BV
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20220195031
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 23, 2022
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Antibodies to CD70
    Patent number: 11072665
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 27, 2021
    Assignee: argenx BVBA
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
    Publication number: 20210139587
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 13, 2021
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20210130452
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: September 29, 2020
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Amino acid sequences that modulate the interaction between cells of the immune system
    Patent number: 10844123
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 10829552
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • ANTIBODIES TO CD70
    Publication number: 20190270823
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 18, 2019
    Publication date: September 5, 2019
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
    Publication number: 20190211101
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20190100584
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 4, 2019
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Amino acid sequences that modulate the interaction between cells of the immune system
    Patent number: 10208115
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 19, 2019
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Amino acid sequences that modulate the interaction between cells of the immune system
    Patent number: 10087251
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 2, 2018
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same
    Patent number: 10017568
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • ANTIBODIES TO CD70
    Publication number: 20170369581
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 19, 2015
    Publication date: December 28, 2017
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
    Patent number: 9822175
    Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: November 21, 2017
    Assignee: Ablynx N.V.
    Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • Amino acid sequences directed against cellular receptors for viruses and bacteria
    Patent number: 9803018
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Amino acid sequences of the present invention may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 31, 2017
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • Antibodies to CD70
    Patent number: 9765148
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir